Wire · opportunities
Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
Regeneron announced positive Phase 2 trial results for baloncibart, a first-in-class NPR1-blocking antibody for postural orthostatic tachycardia syndrome (POTS), showing significant heart rate reduction and symptom improvement. The company plans to initiate a pivotal Phase 3 trial in early 2027, aiming to address the large unmet need for POTS treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Nov 2026 and 13 Nov 2026.
◆ ◆ The Wire takeaway
You can capitalise on a rare opportunity as the first therapy for POTS nears approval, with Regeneron's baloncibart advancing to pivotal testing. Prepare to move early in patient support and related diagnostics ahead of emerging treatment options.
◆ Coverage
2 sources · first reported 12 Nov 2026 · latest 13 Nov 2026
◆ Related on Wire
◆ Topics